rial eff nent icipant in RC who r ethodo our m icipan ived th studies partici

Papers

Systematic review to determine whether participation in a trial influences outcome

Gunn Elisabeth Vist, Kåre Birger Hagen, P J Devereaux, Dianne Bryant, Doris Tove Kristoffersen, Andrew David Oxman

Abstract

Objective To systematically compare the outcomes of participants in randomised controlled trials (RCTs) with those in comparable non-participants who received the same or similar treatment.

Data sources Bibliographic databases, reference lists from eligible articles, medical journals, and study authors. Review methods RCTs and cohort studies that evaluated the clinical outcomes of participants in RCTs and comparable non-participants who received the same or similar treatment. Results Five RCTs (six comparisons) and 50 cohort studies (85 comparisons) provided data on 31 140 patients treated in RCTs and 20 380 comparable patients treated outside RCTs. In the five RCTs, in which patients were given the option of participating or not, the comparisons provided limited information because of small sample sizes (a total of 412 patients) and the nature of the questions considered. 73 dichotomous outcomes were compared, of which 59 reported no statistically significant differences. For patients treated within RCTs, 10 comparisons reported significantly better outcomes and four reported significantly worse outcomes. Significantly heterogeneity was found ($I^2 = 89\%$) among the comparisons of 73 dichotomous outcomes; none of our a priori explanatory factors helped explain this heterogeneity. The 18 comparisons of continuous outcomes showed no significant differences in heterogeneity ($I^2 = 0\%$). The overall pooled estimate for continuous outcomes of the effect of participating in an RCT was not significant (standardised mean difference 0.01, 95% confidence interval -0.10 to 0.12).

Conclusion No strong evidence was found of a harmful or beneficial effect of participating in RCTs compared with receiving the same or similar treatment outside such trials.

Introduction

Properly conducted randomised controlled trials (RCTs) provide the strongest evidence of the effects of treatment.¹ It is, however, controversial as to whether participants of such trials benefit directly or whether these studies are solely for the benefit of future patients. In addition, there is much scepticism about the applicability of the results to usual practice.²

Four reviews that considered whether it is beneficial or harmful to participate in RCTs drew varied conclusions.³⁻⁶ These reviews compared patients who were treated within trials with those treated outside the trials, regardless of differences between the clinical interventions or between the participants and non-participants. It is therefore uncertain whether the results

BMJ VOLUME 330 21 MAY 2005 bmj.com

reflect the effects of participating in an RCT (trial effects), differences in the clinical interventions (treatment effects), or differences between participants and non-participants. We determined whether the outcomes of participants in RCTs differed from those of comparable non-participants who received the same or similar treatment.

Methods

Our review was undertaken as a Cochrane methodology review (see Cochrane Library for fuller details of our methods and updated versions of the review).⁷

We included studies that compared participants in RCTs with comparable non-participants who received the same or similar treatment. We included observational studies and RCTs in which participation or the option of participation was randomly allocated.

Search strategies


We used seven strategies to identify relevant studies: consultation with experts; search of personal files; electronic searches of the Cochrane central register of controlled trials, Medline, Embase, the Cochrane methodology register, and PsycINFO; a review of reference lists from eligible articles; and a search of PubMed using the "related articles" feature and SciSearch. We also hand searched articles published in 2000 in five medical journals (*BMJ, Annals of Internal Medicine, JAMA, Lancet*, and *New England Journal of Medicine*) to identify RCTs with over 200 patients and at least 100 eligible non-participants. Studies' authors were contacted for data on the treatment and outcomes of eligible non-participants.

Assessment of study eligibility

Two reviewers independently assessed each article for eligibility. Disagreements were resolved by discussion. A third reviewer was consulted when consensus could not be reached.

Data abstraction

Two reviewers independently abstracted data from eligible studies. Each study was assessed for selection bias (differences between participants and non-participants), detection bias, and exclusion bias (losses to follow-up). On the basis of the combined risks of the three biases, we grouped each comparison into overall quality groups (randomised, controlled comparisons, partially controlled comparisons, and poorly controlled comparisons) for analysis. Missing data were sought from the investigators.






Fig 1 Selection process of eligible studies

Analysis

We compared the experimental group of the RCT with their respective eligible non-participants who received the treatment and the control group and eligible non-participants who received the control treatment outside of the trial. For each comparison, we analysed the main outcome, and, when reported, we analysed mortality separately. For all of the included comparisons we used the main outcome as reported by the investigators. We analysed the dichotomous and continuous results separately. The results are reported as relative risks with 95% confidence intervals, using adjusted estimates when available. For a summary of the dichotomous results in one table, we calculated the associated standard error from the natural logarithm of the unadjusted relative risk. Heterogeneity was assessed by χ^2 test and the I² statistic using RevMan version 4.2.8 For the unadjusted relative risk analysis, we used the Mantel-Haenszel test in RevMan. A fixed effect model was used to calculate summary statistics if no statistically significant (P<0.10) heterogeneity was found among similar comparisons. For statistically heterogeneous results we described the variation in the estimates and key explanatory factors; where possible relating the explanatory factors to observed differences in estimates of the effects of participation. We constructed a funnel plot to explore the possibility of publication bias.

Results

Overall, 55 studies, totalling 91 comparisons, met our inclusion criteria (fig 1). Forty one studies are still awaiting assessment, which currently cannot be included or excluded on the basis of the published information.

We identified five RCTs (six comparisons) in which patients were randomised according to whether they had the option to participate. These studies provided limited data because of their small sample sizes and the nature of the questions considered. Two studies randomised 82 patients to "n of 1 trials" compared with standard practice—that is, randomised, double blind, multiple crossover comparisons of an active drug with a placebo in a single patient.^{9 10} One study (60 patients) measured spontaneously self reported side effects in patients who had or had not been informed that they were in an RCT.¹¹ One study (227 patients) reported satisfaction among patients randomised to an RCT compared with patients randomised to a patient preference trial in which they had a choice of treatment.¹² Another study (43 patients) reported pain reduction among patients randomised to an RCT compared with those who were not invited to

	Number of comparisons	Number of similar results	Number better in RCT	Number worse in RC1
Selection bias:				
Low risk	6	6	_	_
No imbalance	22	19	1	2
Adjusted results	12	7	4	2
Partially controlled	18	15	2	1
Poorly controlled	33	30	3	_
Detection bias:				
Low risk*	78	66	8	3
Partially met, similarly measured	5	3	2	1
High risk	8	8	_	_
Exclusion bias:				
No losses to follow up	38	32	4	2
1 person to 20% lost to follow up	33	30	2	1
>20% loss to follow up	11	10	_	1
Unclear	9	4	4	1
Reasons for non-participa	tion:			
Refused	27	18	7	2
Refused because of preference	23	20	1	2
RCT versus preference trial	16	15	_	1
Not invited	8	8	_	_
Treated by non-participating clinicians	1	1	—	_
Different skills required for	or treatment:			
Surgery and procedures	28	25	1	2
Drug treatment	22	17	4	1
Radiology	14	12	1	1
Usual care	9	8	1	_
Counselling and education	8	8	_	_
Watchful waiting	7	6	_	1
Different clinical area:				
Oncology	28	23	3	2
Obstetrics and gynaecology	14	12	2	1
Cardiology	13	10	2	1
Other internal medicine	11	9	2	_
Psychology and drug misuse	9	9	_	_
Paediatrics	8	7	_	1
Respiration	2	2		

Table 1 Summary of studies included in sensitivity analysis

RCT=randomised controlled trial.

*Outcomes were measured in same way.

participate.¹³ None of these studies found significant differences in outcomes between patients treated in or outside RCTs.

Non-randomised cohort studies

We identified 50 cohort studies (85 comparisons) totalling 30 862 patients participating in RCTs compared with 20 246 patients treated outside RCTs.¹⁴⁻⁶³ Seventy comparisons comprised dichotomous outcomes, of which 12 reported adjusted estimates, and 15 comparisons comprised continuous outcomes.

We found significant heterogeneity ($I^2 = 89.0\%$) among the results of comparisons with dichotomous main outcomes (fig 2); these results were therefore not pooled. Of these 73 comparisons, 59 reported no significant differences between outcomes for patients treated in RCTs and those receiving similar treatments outside RCTs; 10 reported significantly better outcomes for patients treated in RCTs, and four reported significantly worse outcomes for patients treated in RCTs.

Study or subcategory	Log (relative risk) (SE)	Relative risk (random) (95% Cl)	Weight (%)	Relative risk (randon (95% Cl)
Randomised	0.01/0.01		o7	4.07 (0.05
Cooper 1997a ¹²	0.24 (0.21)	-	67.57	1.27 (0.85 to 1.90)
Cooper 1997b ¹²	-0.14 (0.39)		29.78	0.87 (0.40 to 1.86)
Dahan 1986 ¹¹	2.20 (1.47)		2.65	9.00 (0.51 to 160.07
djusted results				
avis 1985 ²⁶	-0.94 (0.15)	_ _	6.64	0.39 (0.29 to 0.52)
eit 2000a ²⁸	0.16 (0.01)		9.90	1.17 (1.15 to 1.19)
eit 2000b ²⁸	-0.06 (0.02)		9.87	0.94 (0.91 to 0.97)
losekilde 2000a ⁴⁴	0.14 (0.11)	+ - -	7.85	1.15 (0.93 to 1.42)
losekilde 2000b ⁴⁴	0.28 (0.42)	e	1.97	1.32 (0.58 to 3.02)
chmoor 1996a ⁵³	0.02 (0.04)	+	9.56	1.03 (0.95 to 1.11)
chmoor 1996b ⁵³	0.01 (0.03)	÷	9.71	1.01 (0.95 to 1.07)
chmoor 1996c ⁵³	-0.33 (0.07)		8.83	0.72 (0.62 to 0.83)
chmoor 1996d ⁵³	-0.06 (0.10)		8.09	0.94 (0.77 to 1.14)
chmoor 1996e ⁵³	0.18 (0.05)	-	9.43	1.20 (1.09 to 1.31)
chmoor 1996f ⁵³	-0.00 (0.09)	-+-	8.47	1.00 (0.84 to 1.18)
Villiford 1993 ⁶⁰	-0.51 (0.03)	•	9.67	0.60 (0.56 to 0.64)
controlled comparisons				
hattacharya 1998 ¹⁸	-0.12 (0.49)		4.90	0.89 (0.34 to 2.30)
lelsing 1998a ³¹	-0.07 (0.14)	— —	21.50	0.93 (0.70 to 1.22)
lelsing 1998b ³¹	-0.08 (0.06)	-	29.08	0.92 (0.83 to 1.03)
ink 1991a ³⁶	-0.11 (0.37)		7.50	0.89 (0.43 to 1.86)
ink 1991b ³⁶	0.06 (0.13)		22.14	1.07 (0.82 to 1.39)
lagel 1998a ⁴⁵	0.24 (0.80)		2.03	1.27 (0.27 to 6.06)
lagel 1998b45	0.75 (1.53)	←	0.58	2.11 (0.10 to 42.37)
licolaides 1994a ⁴⁶ licolaides 1994b ⁴⁶	0.15 (0.32) -1.14 (0.64)		9.23 3.04	1.16 (0.61 to 2.19) 0.32 (0.09 to 1.12)
	× ,	`	0.04	0.02 (0.03 (0 1.12)
artially controlled compariso lichert-Toft 1988a ²⁰	ns 0.43 (0.45)	_	2 00	1 52 (0 62 +0 2 70)
lichert-Toft 1988b ²⁰	0.43 (0.45) 1.03 (0.51)		3.89 3.23	1.53 (0.63 to 3.73)
ASS 1984a ²¹	0.06 (0.23)		9.75	2.79 (1.04 to 7.53) 1.06 (0.67 to 1.68)
ASS 1984b ²¹	0.07 (0.20)		11.58	1.07 (0.73 to 1.59)
hauhan 1991 ²²	0.07 (0.20)		4.84	1.02 (0.47 to 2.21)
lagett 1984a ²⁴	-0.29 (0.56)		2.72	0.75 (0.25 to 2.23)
lagett 1984b ²⁴	-1.10 (1.59)		0.38	0.33 (0.01 to 7.52)
creutzig 1993a ²⁵	1.47 (1.03)		0.88	4.33 (0.58 to 32.48)
creutzig 1993b ²⁵	0.12 (0.36)		5.50	1.13 (0.55 to 2.29)
orbes 2000 ²⁹	-0.58 (0.48)		3.59	0.56 (0.22 to 1.43)
lenshaw 1993a ³²	1.68 (0.60)	- I	2.42	5.36 (1.66 to 17.28)
lenshaw 1993h ³²	-0.53 (0.90)	<hr/>	1.13	0.59 (0.10 to 3.44)
iu 1998a ³⁷	-1.09 (1.21)	<	0.64	0.34 (0.03 to 3.64)
iu 1998b ³⁷	-0.13 (0.90)	< <u>−</u>	1.13	0.87 (0.15 to 5.11)
/lartinez-Amenos 1990a ³⁹	-0.31 (0.14)		15.08	0.73 (0.56 to 0.97)
/lartinez-Amenos 1990b ³⁹	-0.03 (0.17)	_	13.29	0.97 (0.70 to 1.35)
3igg 2000a ⁵⁰	-1.46 (0.61)		2.30	0.23 (0.07 to 0.77)
Rigg 2000b ⁵⁰	0.28 (0.61)		2.33	1.32 (0.40 to 4.37)
trandberg 1995 ⁵⁴	-0.52 (0.14)		15.32	0.59 (0.45 to 0.78)
Poorly controlled comparisons				
Balmukhanov 1989a ¹⁴	-0.91 (0.75)	← ■	0.77	0.40 (0.09 to 1.76)
almukhanov 1989b ¹⁴	-0.10 (0.18)		6.02	0.91 (0.63 to 1.30)
aum 1979 ¹⁵	-1.30 (0.66)	<	0.97	0.27 (0.07 to 0.99)
erglund 1997 ¹⁷	0.49 (0.28)		3.77	1.63 (0.94 to 2.83)
ijker 2000a ¹⁹	-0.42 (0.54)		1.39	0.65 (0.23 to 1.88)
ijker 2000b ¹⁹	0.78 (0.45)		1.90	2.18 (0.91 to 5.25)
hilvers 2001a ²³ hilvers 2001b ²³	-0.07 (0.11)	— — —	8.26	0.93 (0.75 to 1.16)
dsmyr 1978 ²⁷	0.12 (0.11)		8.39 0.35	1.13 (0.91 to 1.39) 0.45 (0.05 to 4.16)
orssell 1989 ³⁰	-0.80 (1.14)		1.06	0.45 (0.05 to 4.16) 0.95 (0.28 to 3.29)
ieler 1998 ³³	-0.05 (0.63)		1.06	0.95 (0.28 to 3.29)
ing 1997a ³⁴	-0.05 (0.63) 0.25 (0.39)		2.38	1.28 (0.60 to 2.75)
ing 1997b ³⁴	-0.16 (0.36)		2.65	0.85 (0.42 to 1.73)
idbrink 1995 ³⁵	-0.34 (0.26)		4.19	0.85 (0.42 to 1.73) 0.71 (0.43 to 1.18)
IACESG 1992a ³⁸	-0.52 (0.60)	<u></u>	1.16	0.59 (0.18 to 1.91)
IACESG 1992a IACESG 1992b ³⁸	0.74 (0.73)		0.80	2.10 (0.50 to 8.81)
loertel 1984 ⁴³	0.31 (0.21)		5.24	1.37 (0.90 to 2.07)
lavforth 1988 ⁴⁹	0.49 (0.58)		1.22	1.63 (0.52 to 5.10)
osen 1987a ⁵¹	-0.21 (0.07)		9.47	0.81 (0.70 to 0.93)
osen 1997b ⁵¹	-0.17 (0.06)	-=-	9.74	0.84 (0.75 to 0.95)
ullivan 1982a ⁵⁵	1.91 (1.39)		0.24	6.75 (0.45 to 102.39
ullivan 1982b ⁵⁵	-2.60 (1.34)	·	0.25	0.07 (0.01 to 1.02)
ullivan 1982c ⁵⁵	0.38 (1.05)	← →	0.41	1.46 (0.19 to 11.35)
Irban 1999 ⁵⁶	0.32 (0.24)		4.66	1.38 (0.87 to 2.19)
Vetzner 1979 ⁵⁸	0.86 (0.50)		1.58	2.35 (0.88 to 6.28)
/ikdahl 1992 ⁵⁹	-0.03 (0.71)		0.85	0.97 (0.24 to 3.90)
amamoto 1992a ⁶¹	-0.25 (0.18)	_ _	6.22	0.78 (0.55 to 1.10)
amamoto 1992h ⁶¹	-0.16 (0.14)	_ _	7.44	0.85 (0.65 to 1.11)
ersin 1996 ⁶²	0.00 (0.45)		1.91	1.00 (0.42 to 2.40)
oung 1996 ⁶³	-0.06 (0.20)		5.64	0.94 (0.64 to 1.38)

Fig 2 Results of dichotomous main outcomes in participants of randomised controlled trials and comparable non-participants who received the same or similar treatment

Study or subcategory	No	In randomised controlled trials Mean (SD)	(No	Dutside of randomised controlled trials Mean (SD)	l Standardised mean difference (fixed) (95% Cl)	Weight (%)	Standardised mean difference (fixed) (95% Cl)
Randomised Bergmann 1994 ¹³ Mahon 1996 ⁹ Mahon 1999 ¹⁰ Subtotal (95% CI) Test for heterogeneity: χ^2 = Test for overall effect: z=0.			25 9 30 64 %	-5.30 (34.00) -3.00 (53.00) -8.00 (63.00)	-+- -+- +-	3.04 1.54 4.55 9.13	-0.50 (-1.12 to 0.11 -0.21 (-1.08 to 0.66 0.23 (-0.27 to 0.74) -0.09 (-0.44 to 0.27
$\begin{array}{c} \textbf{Controlled comparison} \\ McKay 1995a^{41} \\ McKay 1995b^{41} \\ McKay 1998a^{42} \\ McKay 1998b^{42} \\ Rovers 2001a^{52} \\ Rovers 2001b^{52} \\ Subtotal (95\% CI) \\ Test for heterogeneity: \chi^{2=} \\ Test for overall effect: z=0. \end{array}$			52 16 29 15 36 97 245	4.90 (7.90) 7.88 (9.97) 2.00 (4.05) 1.60 (3.38) 30.00 (15.31) 71.00 (20.10)		3.66 2.54 5.47 3.28 7.72 14.34 37.02	-0.20 (-0.76 to 0.36 -0.10 (-0.78 to 0.57 -0.09 (-0.55 to 0.37 0.24 (-0.36 to 0.83) 0.32 (-0.07 to 0.71) -0.04 (-0.33 to 0.24 0.03 (-0.15 to 0.21)
Partially controlled compr McCaughey 1998 ⁴⁰ Villamaria 1997a ⁵⁷ Villamaria 1997b ⁵⁷ Subtotal (95% CI) Test for heterogeneity: χ^2 = Test for overall effect: z=0.	6 30 30 66 5.61, df=		20 8 16 44 %	5.10 (5.50) -37.22 (0.65) -37.38 (0.84)	 	1.25 1.86 3.13 6.24	1.01 (0.05 to 1.97) -0.49 (-1.28 to 0.30 0.13 (-0.48 to 0.74) 0.12 (-0.31 to 0.55)
Poorly controlled compari Bedi 2000a ¹⁶ Bedi 2000b ¹⁶ Paradise 1984b ⁴⁷ Paradise 1984b ⁴⁷ Paradise 1990a ⁴⁸ Paradise 1990b ⁴⁸ Subtotal (95% CI) Test for heterogeneity: χ^2 = Test for overall effect: z=0.	52 51 38 35 52 47 275 2.39, df=		140 80 44 34 46 67 411	14.40 (9.80) 14.00 (9.30) 1.05 (1.22) 2.41 (2.27) 11.19 (7.23) 13.41 (9.78)	* * * *	11.39 9.35 6.08 5.18 7.32 8.30 47.62	0.08 (-0.24 to 0.40) 0.08 (-0.27 to 0.43) -0.25 (-0.69 to 0.18 0.11 (-0.36 to 0.58) -0.13 (-0.52 to 0.27 0.04 (-0.33 to 0.41) 0.00 (-0.15 to 0.16)
Total (95% CI) Test for heterogeneity: χ^2 = Test for overall effect: z=0.			764 %		•	100.00	0.01 (-0.10 to 0.12)

Fig 3 Results of continuous main outcomes in participants of randomised controlled trials and comparable non-participants who received the same or similar treatment

Figure 3 shows the results of the 18 comparisons with continuous main outcomes. We found no significant heterogeneity ($I^2 = 0\%$). The pooled estimate found no differences in outcomes for patients treated in and outside RCTs (standardised mean difference 0.01, 95% confidence interval -0.10 to 0.12).

In 17 studies (32 comparisons) with data on mortality (fig 4), we found significant heterogeneity ($I^2 = 88.8\%$); the results were therefore not pooled. In 24 of the 32 comparisons we found no significant difference in mortality. Four comparisons reported a significant lower risk of mortality for patients treated in RCTs and four comparisons reported a significantly higher risk of mortality.

Separate subgroup analyses could not explain the observed heterogeneity by the different types of eligible non-participants, treatments, clinical specialities, or study quality (selection bias, detection bias, and exclusion bias). The table summarises the studies included in the sensitivity analysis.

The funnel plot of the dichotomous comparisons showed no asymmetry (fig 5), indicating a low risk of publication bias.

Discussion

Our systematic review found no strong evidence of a harmful or beneficial trial effect of participating in randomised controlled trials (RCTs). The five included RCTs provided limited evidence because of their small sample sizes and the nature of the questions they considered, but they did show that it is possible to consider questions about the effects of participating in RCTs by using randomised designs. Our interpretation of the 50 non-randomised cohort studies was limited by the quality and size of the comparisons and the wide variations in participants, clinical interventions, and outcomes. Most of the 85 non-randomised cohort comparisons found no statistically significant differences, although 10 reported better outcomes for patients in RCTs.

Previous reviews that considered a less precise question than the one we evaluated drew varied conclusions. For example, one identified 14 articles reporting data from 21 trials and concluded that, if anything, randomised trials tend to have beneficial rather than harmful effects.⁴ Another review included seven of these 14 articles and 17 additional articles.⁶ Only eight of the studies compared trial patients with non-trial patients who met the same eligibility criteria, and it was only possible to separate treatment effects from trial effects in three of these trials. A further review found 10 comparisons on survival or quality of life of patients treated in RCTs for life threatening illnesses (eight were cancer treatments) with those treated outside RCTs.⁵ It found evidence of longer survival in participants, but the authors were not confident of the results.

Study or subcategory	Log (relative risk) (SE)	Relative risk (random) (95% Cl)	Weight (%)	Relative risk (random) (95% Cl)
Adjusted mortality				
Davis 1985 ²⁶	-0.94 (0.15)	_ _	7.10	0.39 (0.29 to 0.52)
Feit 2000a ²⁸	-0.06 (0.02)		13.09	0.94 (0.91 to 0.97)
Feit 2000b ²⁸	0.16 (0.01)		13.16	1.17 (1.15 to 1.19)
Schmoor 1996a ⁵³	0.00 (0.05)	+	11.95	1.00 (0.90 to 1.11)
Schmoor 1996b53	0.17 (0.04)	-	12.57	1.18 (1.10 to 1.27)
Schmoor 1996c ⁵³	-0.13 (0.09)		10.13	0.88 (0.74 to 1.05)
Schmoor 1996d ⁵³	0.43 (0.09)		9.86	1.54 (1.28 to 1.85)
Schmoor 1996e ⁵³	0.26 (0.05)	-	11.99	1.29 (1.17 to 1.43)
Schmoor 1996f ⁵³	0.10 (0.09)		10.13	1.10 (0.93 to 1.31)
Unadjusted mortality				
CASS 1984a ²¹	0.06 (0.23)	_	6.87	1.06 (0.67 to 1.68)
CASS 1984b ²¹	0.07 (0.20)	_	8.53	1.07 (0.73 to 1.59)
Helsing 1998a ³¹	-0.07 (0.14)		12.20	0.93 (0.70 to 1.22)
Helsing 1998b ³¹	-0.08 (0.06)	-	19.32	0.92 (0.83 to 1.03)
Kieler 1998 ³³	-0.05 (0.63)		1.31	0.95 (0.28 to 3.29)
King 1997a ³⁴	0.25 (0.39)	_	3.13	1.28 (0.60 to 2.75)
King 1997b ³⁴	-0.16 (0.37)	_	3.52	0.85 (0.42 to 1.73)
Lidbrink 1995 ³⁵	-0.34 (0.26)	_	5.98	0.71 (0.43 to 1.18)
Link 1991a ³⁶	1.19 (1.39)		0.28	3.28 (0.22 to 49.81)
Link 1991b ³⁶	0.00 (1.97)	\leftarrow	0.14	1.00 (0.02 to 47.78)
Moertel 1984 ⁴³	0.31 (0.21)		7.88	1.37 (0.90 to 2.07)
Nagel 1998a ⁴⁵	0.24 (0.80)	_	0.84	1.27 (0.27 to 6.06)
Nagel 1998b ⁴⁵	0.75 (1.53)	<	0.23	2.11 (0.10 to 42.37)
Nicolaides 1994a ⁴⁶	0.15 (0.32)	· · · · · · · · · · · · · · · · · · ·	4.24	1.16 (0.61 to 2.19)
Nicolaides 1994b ⁴⁶	-1.14 (0.64)	←∎─────┼	1.27	0.32 (0.09 to 1.12)
Playforth 1988 ⁴⁹	0.49 (0.58)		1.52	1.63 (0.52 to 5.10)
Rigg 2000a ⁵⁰	-1.46 (0.61)		1.38	0.23 (0.07 to 0.77)
Rigg 2000b ⁵⁰	0.28 (0.61)	·	1.39	1.32 (0.40 to 4.37)
Strandberg 1995 ⁵⁴	-0.52 (0.14)		12.45	0.59 (0.45 to 0.78)
Sullivan 1982a ⁵⁵	0.15 (1.50)	<	0.24	1.16 (0.06 to 22.10)
Sullivan 1982b ⁵⁵	-0.90 (1.48)	<	0.25	0.41 (0.02 to 7.47)
Sullivan 1982c ⁵⁵	-0.10 (1.60)	< =	0.21	0.90 (0.04 to 20.82)
Urban 1999 ⁵⁶	0.32 (0.24)	· · · · · · · · · · · · · · · · · · ·	6.81	1.38 (0.87 to 2.19)
		0.2 0.5 0 2 5	5	
	Favours being in random	nised controlled trial Favours being outs	ide randomised controlle	d trial

Fig 4 Comparison of mortality between participants of randomised controlled trials and comparable non-participants who received the same or similar treatment

Our review differs from these reviews in several ways, including the scope and comprehensiveness of our search, our method of analysis, and the question we asked, which controlled for differences in the effects of different interventions and differences between participants and non-participants. (See bmj.com for an evidence profile of our results according to the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) Working Group.) Our results are based mainly on comparisons of cohorts and are subject to the usual uncertainty associated with observational studies.¹ Additionally, we could not explain the significant heterogeneity between studies, which affects our confidence in the results and reduces the overall quality of information. Other relevant studies apart from those included in this review may exist, as indicated by the number of studies awaiting assessment and the difficulty we and others had




Fig 5 Funnel plot of dichotomous comparisons in participants of randomised controlled trials and comparable non-participants who received the same or similar treatment

in searching for this type of study in electronic databases. As we did not find evidence of publication bias, it is unlikely that the studies that we failed to identify would provide strong evidence of either harmful or beneficial effects.

An important corollary of this finding is that it counters suggestions that the results of RCTs cannot be applied to usual clinical practice, because most of the studies found no significant difference in outcomes for participants of RCTs compared with comparable non-participants who received similar treatment.

In most cases, RCTs seem to provide estimates of treatment effects that are applicable to comparable patients who receive similar interventions in usual clinical practice. In addition to being informed about the risks and harms of an intervention when invited to participate in RCTs, patients can be told that, independently of the effects of the interventions being compared, participating in a trial is likely to result in similar outcomes to patients who receive the same or similar treatment outside of the trial.

We thank Dave Sackett for initiating this review, for his contributions to the protocol, and for his support; Lena Nordheim for help with the search strategy; and the following for additional information about their studies: S M Albert, B J Barrett, J M Bennett, S B Black, S S Brehm, G Berglund, J F Bergmann, N Bijker, M Blichert-Toft, L Boros, J G Cairncross, K M Carroll, D W Chadwick, S P Chauhan, C Chilvers, G P Clagett, C J Cohen, K Collins, J S Cooper, K G Cooper, V Cottin, U Creutzig, S Davis, E P DiMagno, J van Eys, P J Ferrone, G M Forbes, J Frisell, B Glimelius, C Gluud, F Guillemin, J C Hauth, M Helsing, D Hellberg, J M Henderson, A M Hutter, L P Jensen, J J C Jonker, T Karrison, S B King, D Kjar, R A Kronmal, R W Licht, E Lidbrink, W F Liu, J K Madsen, J L Mahon, M A Malangoni, C Marcocci, J R McKay, M P Mourits, C Moynihan, G R Mundy, C D Naylor, M G Neuwirth, J R O'Fallon, J L Paradise, A Pinchera, M J Playforth, A V Pollock, P D Rokke, M A Rosen, M M Rovers, R G Rychtarik, B Schmidt, C Schmoor, B E Sha, J H Shelhamer, B G Stegmayr, C A Stiller, J M Stone, R Takolander,

What is already known on this topic

Some people believe that participation in a randomised controlled trial (RCT) increases a patient's risk of a bad outcome

Some people claim that the results of RCTs are not applicable to usual clinical practice

What this study adds

Participants in RCTs had similar outcomes to comparable patients who received the same or similar treatment outside the trial

The results of RCTs are therefore applicable to comparable patients in usual clinical practice

I F Tannock, P Vestergaard, B Ward, C Weijer, D J Weisdorf, D G Wyse, B Yersin, and V L Yu

Contributors: GEV carried out the literature search. GEV and KBH selected the studies. GEV, KBH, PJD, and DB extracted the data. GEV, DTK, and ADO analysed the data. GEV, KBH, PJD, DB, and ADO drafted the manuscript. GEV, KBH, PJD, and ADO developed the protocol and review. DB hand searched the five medical journals. GEV is guarantor for the paper.

Funding: Norwegian Health Services Research Centre, McMaster University, and the Nuffield Trust.

Competing interests: None declared.

Ethical approval: Not required.

- Kunz R, Vist G, Oxman AD. Randomisation to protect against selection bias in health-care trials (Cochrane methodology review). Issue 4. Oxford: Update Software, 2002. Rothwell PM. External validity of randomised controlled trials: "To whom do the results of this trial analy?" June 2002 6267 620 620 1
- 2 of this trial apply?" Lancet 2005;365:82-93.
- 3 Stiller CA. Centralised treatment, entry to trials and survival. Br J Cancer 1994;70:352-62.
- 4
- b2. Braunholtz DA, Edwards SJL, Lilford RJ. Are randomized clinical trials good for us (in the short term)? Evidence for a "trial effect." *J Clin Epidemiol* 2001;54:217-24. The Emergency Care Research Institute 2002. Patients' reasons for participation in clinical trials and effect of trial participation on patient outcomes. www.ecri.org/ Patient_Information/Patient_Reference_Guide/evidence.pdf (accessed Nov 2004). Peppercorn JM, Weeks JC, Cook EFC, Joffe S. Comparison of outcomes in cancer regions treated within and outside chinical trials concernue of formework and structured. 5
- 6 patients treated within and outside clinical trials: conceptual framework and structured review. *Lancet* 2004;363:263-70.
- 7 Vist GE, Hagen KB, Devereaux P, Bryant D, Kristoffersen DT, Oxman AD. Outcomes of patients who participate in randomised controlled trials compared to similar patients receiving similar interventions who do not participate (Cochrane methodology
- reviews). Issue 1. Oxford: Update Software, 2005. Higgins JP, Thompson SG. Quantifying heterogeneity in meta-analysis. Stat Med 2002:21:1539-58
- Mahon J, Laupacis A, Donner A, Wood T. Randomised study of n of 1 trials versus standard practice. *BMJ* 1996;312:1069-74. 10 Mahon JL, Laupacis A, Hodder RV, McKim DA, Paterson NAM, Wood TE, et al. Theo-
- phylline for irreversible chronic airflow limitation. A randomized study comparing n of 1 trials to standard practice. *Chest* 1999;115:38-48.
- 11 Dahan R, Caulin C, Figea L, Kanis JA, Caulin F, Segrestaa JM. Does informed consent influence therapeutic outcome? A clinical trial of the hypnotic activity of placebo in
- influence therapeutic outcome? A clinical trial of the hypnotic activity of placebo in patients admitted to hospital. *BMJ* 1986;293:363-4.
 12 Cooper KG, Grant AM, Garratt AM. The impact of using a partially randomised patient preference design when evaluating alternative managements for heavy menstrual bleeding. *Br J Obstet Gynaecol* 1997;104:1367-73.
 13 Bergmann JF, Chassany O, Gandiol J, Deblois P, Kanis JA, Segrestaa JM, et al. A randomised clinical trial of the effect of informed consent on the analgesic activity of placebo and naproxen in cancer pain. *Clin Trials Metaanal* 1994;29:41-7.
 14 Boltwichenen CP. Beichener AA. Aithongers TJ. Metamali JSM: J. Beichener AJ. Althona and J. Beichener AA. Aithongers TJ. Metamali JSM: J. Beichener AJ. Antibacture TJ. Metamali JSM: J. Beichener AJ. Metamali JSM: J. Beichener AJ. Antibacture TJ. Metamali JSM: J. Beichener AJ. Antibacture TJ. Metamali JSM: J. Beichener AJ. J. Beichener AJ. J. Beichener AJ. J. Beichener AJ. Metamali JSM: J. Beichener AJ. Met
- 14 Balmukhanov SB, Beisebaev AA, Aitkoolova ZI, Mustaphin JS, Philippenko VI, Rismu-hamedova RS, et al. Intramural and parametrial infusion of metronidazole in the radiotherapy of uterine cervix cancer: preliminary report. Int J Radiation Oncol Biol Phys 1989;16:1061-3
- 1989;16:1061-3.
 Baum F, Sather H, Nachman J, Seinfeld J, Kritvit W, Leikin S, et al. Relapse rates following cessation of chemotherapy during complete remission of acute lymphocytic leukemia: a report from childrens cancer study group. *Med Pediatr Oncol* 1979;7:25-34.
 Bedi N, Chilvers C, Churchill R, Dewey M, Duggan C, Fielding K, et al. Assessing effectiveness of treatment of depression in primary care: partially randomised preference trial. *Br J Psychol* 2000;177:312-8.
 Partial G D, Brede G, Catter G, Katter M, Garden D, Lehouch M, Catter M, Ca
- 17 Berglund G, Bolund C, Gustafsson UL, Sjoden PO. Is the wish to participate in a can-
- Defgnitt O, Bound S, Gouanasso C, Solecti N, Orache W, Born M, Charles M, Sanda M, Canara M,
- selection on the applicability of results from a randomised clinical trial (EORTC

10853) investigating breast-conserving treatment for DCIS. Breast conserving therapy for ductal carcinoma in situ. PhD Thesis, 2000.

- Blichert-Toft M, Brincker H, Andersen JA, Andresen KW, Axelsson CK, Mouridsen HT, 20 et al.. A Danish randomized trial comparing breast-conserving therapy with mastectomy in mammary carcinoma: preliminary results. Acta Oncologica 1988:27:671-7.
- Coronary artery surgery study (CASS): a randomised trial of coronary artery bypass surgery. Comparability of entry characteristics and survival in randomized patients and nonrandomized patients meeting randomization criteria. J Am Coll Cardiol 1984;3:114-
- 22 Chauhan SP, Rutherford SE, Hess LW, Morrison JC. Prophylactic intrapartum amnioinfusion for patients with oligohydramnios: a prospective randomized study. J Reprod Med 1991;37:817-20.
- Chilvers C, Dewey M, Fielding K, Gretton V, Miller P, Palmer B, et al. Antidepressant drugs and generic counselling for treatment of major depression in primary care: ran-domised trial with patient preference arms. *BMJ* 2001;322:772-5.
- Clagett GP, Youkey JR, Bringham RA, Orecchia PM, Salander JM, Collins GJ, et al. Asymptomatic cervical bruit and abnormal ocular pneumoplethysmography: a
- prospective study comparing two approaches to management. Surgery 1984;96:523-30. Creutzig U, Ritter J, Zimmermann M, Schellong G. Does cranial irradiation reduce the risk of bone marrow relapse in acute myelogenous leukemia? Unexpected results of the childhood acute myelogenous leukemia study BFM-87. *J Clin Oncol* 1993;11:279-86.
 26 Davis S, Wright PW, Schulman SF, Hill LD, Pinkham RD, Johnson LP, et al. Participants
- in prospective, randomized clinical trials for resected non-small cell lung cancer have improved survival compared with nonparticipants in such trials. *Cancer* 1985;56:1710-8.
- Edsmyr F, Esposti PL, Johansson B, Strindberg B. Clinical experimental randomized study of 2.6-CIS-diphenylhexamethylcyclotetrasiloxane and estramurine-17-phosphate in the treatment of prostatic carcinoma. *J Urol* 1978;120:705-7. Feit F, Brooks MM, Sopko G, Keller NM, Rosen A, Krone R, et al. Long-term clinical et al. Long-term clinical
- 28 outcome in the bypass angioplasty revascularization investigation registry: comparison with the randomized trial. *Circulation* 2000;101:2795-802.
- Forbes GM, Collins BJ, Nirous oxide for colonoscopy: a randomized controlled study. Gastrointest Endosc 2000;51:271-7.
- 30 Forssell C, Takolander R, Bergqvist D, Johansson A, Persson NH. Local versus general anaesthesia in carotid surgery. A prospective, randomised study. Eur J Vasc Surg 10009 J 2020 00 J 1989:3:503-9.
- Helsing M, Bergman B, Thaning L, Hero U, for the Joint Lung Cancer Study Group. 31 Quality of life and survival in patients with advanced non-small cell lung cancer recei
- guanty of the and surviva in patients with davanced non-sinial centring carter receivering supportive care plus chemotherapy with carboplatin and etoposide or supportive care only. A multicentre randomised phase III trial. *Eur J Cancer* 1998;34:1036-44.
 Henshaw RC, Naji SA, Templeton AA. Comparison of medical abortion with surgical vacuum aspiration: women's preferences and acceptability of treatment. *BMJ* 1000-67514-57. 1993.307.714-7
- Kieler H, Hellberg D, Nilsson S, Waldenstrøm U, Axelsson O. Pregnancy outcome among non-participants in a trial on ultrasound screening. Ultrasound Obstet Gynecol 1998;11:104-9.
- King III SB, Barnhart HX, Kosinski AS, Weintraub WS, Lembo NJ, Petersen JY, et al. 34Angioplasty or surgery for multivessel coronary artery disease: comparison of eligible registry and randomized patients in the EAST trial and influence of treatment selection on outcomes. Am J Cardiol 1997;79:1453-9.
- Lidbrink E, Frisell J, Rosendahl I, Rutqvist LE. Nonattendance in the Stockholm mammography screening trial: relative mortality and reasons for nonattendance. Breast Cancer Res Treat 1995;35:267-75.
- Link MP, Goorin AM, Horowitz M, Meyer WH, Belasco J, Baker A, et al. Adjuvant chemotherapy of high-grade osteosarcoma of the extremity. Updated results of the multi-institutional osteosarcoma study. *Clin Orthop Relat Res* 1991;270:8-14. Liu WF, Harrington T. The need for delivery room intubation of thin meconium in the low risk newborn: a clinical trial. *Am J Perinatol* 1998;15:675-82. 36
- 37 Mayo Asymptomatic Carotid Endarterectomy Study Group. Results of a randomized 38
- controlled trial of carotid endarterectomy for asymptomatic carotid stenosis. Maya Clinic Proc 1992:67:513-8. Martinez-Amenos A, Ferre MLF, Vidal CM, Rocasalbas JA. Evaluation of two educative
- models in primary care hypertension programme. *J Hum Hypertens* 1990;4:362-4. McCaughey ES, Mulligan J, Voss LD, Betts PR. Randomised trial of growth hormone in 40
- short normal girls. *Lancet* 1998;351:940-4. McKay JR, Alterman AI, McLellan AT, Snider EC, O'Brian CP. Effect of random versus
- formal of a signment in a comparison of inpatient and day hospital rehabilitation for male alcoholics. J Consult Clin Psychol 1995;63:70-8.
- McKay JR, Alterman AI, McLellan AT, Boardman CR, Mulvaney FD, O'Brian CP. Random versus nonrandom assignment in the evaluation of treatment for cocaine abusers. J Consult Clin Psychol 1998;66:697-701.
- Moertel CG, Childs DS, O'Fallon JR, Holbrook MA, Schutt AJ, Reitemeier RJ. Combined 5-fluorouracil and radiation therapy as a surgical adjuvant for poor 43 prognosis gastric carcinoma. J Clin Oncol 1984;2:1249-54. Mosekilde L, Beck-Nielsen H, Sørensen OH, Nielsen SP, Charles P, Vestergaard P, et al.
- 44 Hormonal replacement therapy reduces forearm fracture incidence in recent postmenopausal women-results of the Danish osteoporosis prevention study Maturitas 2000;36:181-93.
- 45 Nagel HTC, Vanderbussche FPHA, Keirse MJNC, Oepkes D, Oosterwijk JC, Beverstock G, et al. Amniocentesis before 14 completed weeks as an alternative to transabdominal chorionic villus sampling: a controlled trial with infant follow-up. Prenat Diagn 1998;18:465-75.
- 46 Nicolaides K, Brizot MdL, Patel F, Snijders R. Comparison of chorionic villus sampling and amniocentesis for fetal karyotyping at 10-13 weeks' gestation. *Lancet* 1994:344:435-9.
- Paradise JL, Bluestone CD, Bachman RZ, Colborn DK, Bernard BS, Taylor FH, et al. 47 Efficacy of tonsillectomy for recurrent throat infection in severely affected children.
- Results of parallel randomized clinical trials. *N Engl J Med* 1984;310:674-83. Paradise JL, Bluestone CD, Rogers KD, Taylor FH, Colborn DK, Bachman RZ, et al. Efficacy of adenoidectomy for recurrent otitis media in children previously treated with tympanostomy-tube replacement. Results of parallel randomized and nonrandomized trials. JAMA 1990;263:2066-73.

- 49 Playforth MJ, Smith GMR, Evans M, Pollock AV. Antimicrobial bowel preparation. Oral, parenteral, or both? *Dis Colon Rectum* 1988;31:90-3.
- 50Rigg JRA, Jamrozik K, Myles PS, Silbert B, Peyton P, Parsons RW, et al. Design of the multicenter Australian study of epidural anesthesia and analgesia in major surgery: the MASTER trial. *Control Clin Trial* 2000;21:244-56.
 Sosen MA, Roizen MF, Eger II EI, Glass RH, Martin M, Dandekar PV, et al. The effect
- of Rosen and Robert M, Pagel H E, Olass KL, Math M, Dahekar F, et al. The effect of nitrous oxide on in vitro fertilization success rate. *Anesthesiol* 1987;67:42-4.
 52 Rovers MM, Straatman H, Ingels K, van der Wilt GJ, van den Broek P, Zielhuis GA. Generalizability of trial results based on randomized versus nonrandomized allocation of OME infants to ventilation tubes or watchful waiting. J Clin Epidemiol 2001;54:789-
- 53 Schmoor C, Oleschewski M, Schumacher M. Randomized and non-randomized patients in clinical trials: experiences with comprehensive cohort studies. *Stat Med* 1996:15:263-71
- 54 Strandberg TE, Salomaa VV, Vanhanen HT, Naukkarin VA, Sarna AJ, Miettinen TA. Mortality in participants and non-participants of a multifactorial prevention study of cardiovascular diseases: a 28 year follow up of the Helsinki businessmen study. Br Heart J 1995;74:449-54. 55 Sullivan MP, Fuller LM, Chen T, Fisher R, Fryer C, Gehan E, et al. Intergroup Hodgkin's
- disease in children study of stages I and II: a preliminary report. Cancer Treat Rep 1982;66:937-47.
- 56 Urban P, Stauffer J-C, Bleed D, Khatchatrian N, Amann W, Bertel O, et al. A randomized evaluation of early revascularization to treat shock complicating acute myocardial infarction. Eur Heart J 1999;20:1030-8.
- 57 Villamaria FJ, Baisden CE, Hillis A, Rajab MH, Rinaldi PA. Forced-air warming is no winardata 1, j. balseth CL, Hins A, Kajao MH, Kinadi TA, Foreceran wai mig is no more effective than conventional methods for raising postoperative core temperature after cardiac surgery. *J Cardiothorac Vasc Anesth* 1997;11:708-11.
 Wetzner SM, Vincent ME, Robbins AH. Ceruletide-assisted cholecystography: a clinical Methods and the convention of the convention of the convention of the convention.
- assessment. Radiology 1979;131:23-6. 59 Wikdahl AM, Granbom L, Stegmayr BG. CAPD bag changing with integrated discon-
- nect system gives lower incidence of peritonitis than with UV-box system. *Adv Perit Dial* 1992;8:276-80.

- 60 Williford WO, Krol WF, Buzby GP. Comparison of eligible randomized patients with two groups of ineligible patients: can the results of the VA total parenteral nutrition clinical trial be generalized? J Clin Epidemiol 1993;46:1025-34
- Yamamoto H, Hughes RW, Schroder KW, Viggiano TR, DiMagno EP. Treatment of benign esophageal stricture by Eder-Puestow or balloon dilators: a comparison 61 between randomized and prospective nonrandomized trials. Mayo Clinic Prod 1992;67:228-36.
- Versin B, Besson J, Duc-Mingot S, Burnand B. Screening and referral of alcoholic patients in a general hospital. A clinical trial. *Eur Addict Res* 1996;2:94-101. Young JDH, MacEwen CJ, Ogston SA. Congenital nasolacrimal duct obstruction in the 62
- 63 second year of life: a multicentre trial of management. Eye 1996;10:485-91.

(Accepted 31 March 2005)

bmj.com 2005;330:1175

BMJ: first published as 10.1136/bmj.330.7501.1175 on 19 May 2005. Downloaded from http://www.bmj.com/ on 23 April 2024 by guest. Protected by copyright

Norwegian Health Services Research Centre, PO Box 7004, 0130 Oslo, Norway Gunn Elisabeth Vist senior researcher

Doris Tove Kristoffersen statistician

Andrew David Oxman researcher

National Research Centre for Rehabilitation in Rheumatology, Diakonhjemmet Hospital, Oslo

Kåre Birger Hagen senior researcher

Clinical Epidemiology and Biostatistics, McMaster University Health Sciences Centre, Hamilton, Ontario, Canada

P J Devereaux senior researcher Dianne Bryant senior researcher

Correspondence to: G E Vist gev@nhsrc.no